Whether implanted as bridge-to-transplantation therapy or destination-therapy, left ventricular assist devices (LVADs) continue to occupy an important niche in the management of advanced heart failure. 1 The majority of the 24,000 devices registered in the Interagency Registry of Mechanically Assisted Circulatory Support database are continuous-flow (CF) LVADs, 2 and long-term use of LVADs in appropriate patient populations has been demonstrated to both improve quality of life and offer a survival benefit. 3 Complications following device placement are well known and include stroke, pump thrombosis, and infection. 4 As implanted foreign bodies, LVADs serve as a nidus for infection, 1 and infections have been common in multiple studies conducted in several countries. 5-7